Trastuzumab deruxtecan, an anti-HER2 ADC, has demonstrated significant efficacy in HER2-overexpressing lung cancer, breast cancer, stomach cancer, and colorectal cancer [10–13], indicating a wide-ranging potential for ADCs in solid tumor therapy. Here, ERBB2 is linked to gastric neoplasm.